- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06495996
Protrieve PROTECTOR-studien (PROTECTOR)
PROTECTOR: Evaluering av sikkerheten og effektiviteten til Protrieve Sheathen for å forhindre klinisk signifikant intraprosedural lungeemboli ved å gi embolisk beskyttelse i IVC under trombektomiprosedyrer for å behandle DVT
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Newport Beach, California, Forente stater, 92663
- Hoag Hospital
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Yale University
-
-
Florida
-
Miami, Florida, Forente stater, 33176
- Baptist Health South Florida
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46204
- IU Health Methodist Hospital
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21218
- MedStar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89102
- University Medical Center Southern Nevada
-
-
New Jersey
-
Englewood, New Jersey, Forente stater, 07631
- Englewood Hospital
-
-
New York
-
New York, New York, Forente stater, 10016
- NYU Langone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, Forente stater, 77555
- University of Texas Medical Branch
-
Houston, Texas, Forente stater, 77030
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Age ≥ 18 years
-
Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
-
Willing and able to provide informed consent
Exclusion Criteria:
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Protrieve Sheath
The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization. |
Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Effectiveness Measure:
Tidsramme: 24 Hours (+-12 Hours)
|
a. Clinically significant PE |
24 Hours (+-12 Hours)
|
|
Primary Safety Measure:
Tidsramme: 24 Hours (+-12 Hours)
|
|
24 Hours (+-12 Hours)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Capture of Thromboembolic Material
Tidsramme: 24 Hours (+-12 Hours)
|
a. Capture and removal of thromboembolic material in the Protrieve funnel, as assessed by proportion of study cases where any material was either entrapped in the funnel or removed via Protrieve |
24 Hours (+-12 Hours)
|
|
Device Success
Tidsramme: 24 Hours (+-12 Hours)
|
b. Device success, defined as successful delivery, deployment, and retrieval of the Protrieve device without complications |
24 Hours (+-12 Hours)
|
|
Venous Access Routes
Tidsramme: 24 Hours (+-12 Hours)
|
c. Thrombectomy via supplementary venous access routes |
24 Hours (+-12 Hours)
|
|
Estimated Percentage of the Protrieve Funnel Obstructed
Tidsramme: 24 Hours (+-12 Hours)
|
d. Estimated percentage of the Protrieve funnel obstructed by clot, as observed by visual inspection or imaging |
24 Hours (+-12 Hours)
|
|
Blood Transfusions
Tidsramme: 24 Hours (+-12 Hours)
|
e. Blood transfusions associated with Protrieve Sheath access site bleeding |
24 Hours (+-12 Hours)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ripal Gandhi, MD, Baptist Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 23-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .